Phase I Study of Veliparib on an Intermittent and Continuous Schedule in Combination with Carboplatin in Metastatic Breast Cancer: A Safety and [18F]‐Fluorothymidine Positron Emission Tomography Biomarker Study

BACKGROUND: Poly(ADP‐ribose) polymerase inhibitors (PARPis) are U.S. Food and Drug Administration (FDA) approved for treatment of BRCA‐mutated metastatic breast cancer. Furthermore, the BROCADE studies demonstrated benefit of adding an oral PARPi, veliparib, to carboplatin and paclitaxel in patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Wesolowski, Robert, Stover, Daniel G., Lustberg, Maryam B., Shoben, Abigail, Zhao, Meng, Mrozek, Ewa, Layman, Rachel M., Macrae, Erin, Duan, Wenrui, Zhang, Jun, Hall, Nathan, Wright, Chadwick L., Gillespie, Susan, Berger, Michael, Chalmers, Jeffrey J., Carey, Alahdra, Balasubramanian, Priya, Miller, Brandon L., Amaya, Peter, Andreopoulou, Eleni, Sparano, Joseph, Shapiro, Charles L., Villalona‐Calero, Miguel Angel, Geyer, Susan, Chen, Alice, Grever, Michael R., Knopp, Michael V., Ramaswamy, Bhuvaneswari
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Breast Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7418347/
https://www.ncbi.nlm.nih.gov/pubmed/32452601
http://dx.doi.org/10.1634/theoncologist.2020-0039

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7418347/
https://www.ncbi.nlm.nih.gov/pubmed/32452601
http://dx.doi.org/10.1634/theoncologist.2020-0039

Ejemplares similares